More apologists. This isn't some start up fractionating rats brains! It's a biotech supposedly getting ready for commercialization. Shame on you, RustyMike...Shame on you!
>>It is not unusual at all for prerevenue companies, especially in the biotech space, to not have quarterly conference calls.
The pre revenue companies I have held may not have calls but do have at least pit out a pr - no call can be due to no analysts covering. The pr was usually an update and trying to show investors what they have to hopefully get some buying of the stock. Here communication is limited. We have a company with a (imo) solid product submitted for approval and little communication and trading near 3 year lows I have had several pre-revenue companies that did much more communication
It is not unusual at all for prerevenue companies, especially in the biotech space, to not have quarterly conference calls.
I don't know which prerevenue biotechs you hold or have held, but all the ones i follow or ever held have most definitely have held quarterly calls with: 1. Financial expenditures, cash position 2. Highlights of the current progress in the Qtr 3. Highlights of upcoming milestones.
They also usually have put out quarterly PRs on the current state of financials, progress and upcoming milestones with projected timelines.
That's pretty much the standard across the ones i've seen or held. So this no Qtrly call or qtry guidance is most definitely not normal to me.